# Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

> **NCT02548650** · PHASE4 · COMPLETED · sponsor: **University of Florida** · enrollment: 66 (actual)

## Conditions studied

- Myocardial Infarction
- Diabetes Mellitus
- Peripheral Arterial Disease

## Interventions

- **DRUG:** Vorapaxar
- **DRUG:** Clopidogrel
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT02548650
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-25
- **Primary completion:** 2018-12
- **Final completion:** 2019-02-14
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2020-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02548650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02548650, "Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02548650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*